News and Views
Nature Medicine 13, 1144 - 1145 (2007)
doi:10.1038/nm1007-1144
Where lies the blame for resistance—tumor or host?
Charles L Sawyers1
- Charles L. Sawyers is in the Human Oncology and Pathogenesis Program at the Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. e-mail: sawyersc@mskcc.org
Abstract
Cytokine signaling from the tumor microenvironment can allow leukemia cells to survive targeted imatinib therapy, in the first report of a non-autonomous resistance mechanism.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
BCR?ABL and CDKN2A: a dropped connectionNature Reviews Cancer Correspondence (01 Jul 2008)
Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in miceOncogene Original Article
Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in miceOncogene Original Article
Efficient tumour formation by single human melanoma cellsNature Article (04 Dec 2008)
